As part of the deal, the two parties will jointly carry out the clinical proof of concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for the high unmet need of FLT3 mutated AML.
MD Anderson will commit its own resources to carry out the clinical trial and BSC will provide the drug supply, study execution, safety monitoring as well as the data management.
Boston Strategics CEO Keizo Koya said: "This is a historical milestone for BSC to build on our concept of ‘True’ Open Innovation by collaborating with such an institution as MD Anderson to create a new effective treatment for AML patients."
The partnership is a further step toward the realization of the company’s ‘True’ Open Innovation platform to develop drug candidates with potential to significantly improve patients’ health care.
MD Anderson Leukemia Department Dr Gautam Borthakur will serve as principal investigator on the clinical trial, which is supported by recent translational data generated by Dr Borthakur, Dr Michael Andreef and colleagues in the Leukemia Department.
The two parties will share the development challenges and risks for these high unmet need patients with advanced hematologic malignancies who need effective and new treatments.